Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-08-09
2011-08-09
Saeed, Kamal (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S256000, C514S337000, C514S374000, C514S469000, C544S238000, C544S333000, C546S282100, C548S235000, C549S467000
Reexamination Certificate
active
07994171
ABSTRACT:
The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.
REFERENCES:
patent: 7265152 (2007-09-01), Saha et al.
patent: 2006/0189606 (2006-08-01), Karp et al.
patent: 2009/0281336 (2009-11-01), Saha et al.
patent: 57-123181 (1982-07-01), None
patent: WO 02/16359 (2002-02-01), None
patent: WO 02/078701 (2002-10-01), None
patent: WO 2004/041201 (2004-05-01), None
patent: WO 2008/125874 (2008-10-01), None
patent: WO 2009/101022 (2009-08-01), None
patent: WO 2009/137493 (2009-11-01), None
patent: WO 2009/137500 (2009-11-01), None
Database Caplus [Online], Chemical Abstracts Service, Columbus, OH, US, Grinev, A.N. et al., “Aminomethyl and aminomethyl derivatives of 5-methoxybenzofuran”, Zhurnal Obshchei Khimii, 33(5):1436-1442, Coden: ZOKHA4; ISSN: 0044-460X (1963), retrieved from STN Database, Accession No. 1963:469003, RN 94004-97-4, 94623-08-2, 95220-34-1, Abstract.
Cheung, M., “The identification of pyrazolo[1,5-a]pyridines as potent p38 kinase inhibitors”, Bioorganic & Medicinal Chemistry Letters, vol. 18, pp. 5428-5430 (2008).
Elsner, J. et al., “Bicyclic melatonin receptor agonists containing a ring-junction nitrogen: Synthesis, biological evaluation, and molecular modeling of the putative bioactive conformation”, Bioorganic & Medicinal Chemistry, vol. 14, pp. 1949-1958 (2006).
Flint, M. et al., “Selection and Characterization of Hepatitis C Virus Replicons Dually Resistant to the Polymerase and Protease Inhibitors HCV-796 and Boceprevir (SCH 503034)”, Antimicrobial Agents and Chemotherapy, vol. 53, No. 2, pp. 401-411 (2009).
Hang, J.Q. et al., “Slow Binding Inhibition and Mechanism of Resistance of Non-nucleoside Polymerase Inhibitors of Hepatitis C Virus”, The Journal of Biological Chemistry, vol. 284, No. 23, pp. 15517-15529 (2009).
Kakehi, A. et al., “Preparation of New Nitrogen-Bridged Heterocycles. XIV. Further Investigation of the Desulfurization and the Rearrangement of Pyrido[1,2-d]-1,3,4-thiadiazine Intermediates”, Chem. Pharm. Bull., vol. 35, No. 1, pp. 156-169 (1987).
Miki, Y. et al., “Acid-Catalyzed Reactions of 3-(Hydroxymethyl)- and 3-(1-Hydroxyethyl)pyrazolo[1,5-a]pyridines”, J. Heterocyclic Chem., vol. 26, pp. 1739-1745 (1989).
Bender John A.
Beno Brett R.
Grant-Young Katharine A.
Han Ying
Hewawasam Piyasena
Bianchi Kristin
Bristol--Myers Squibb Company
Epperson James
Saeed Kamal
LandOfFree
Compounds for the treatment of hepatitis C does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds for the treatment of hepatitis C, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds for the treatment of hepatitis C will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2668789